Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Express Scripts
AstraZeneca
Johnson and Johnson
Moodys

Last Updated: February 3, 2023

CLINICAL TRIALS PROFILE FOR DEXLANSOPRAZOLE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Dexlansoprazole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00251693 ↗ Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis Completed Takeda Phase 3 2005-12-01 The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
NCT00251719 ↗ Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis Completed Takeda Phase 3 2005-12-01 This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically proven erosive esophagitis.
NCT00251745 ↗ Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed Takeda Phase 3 2005-12-01 The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
NCT00251758 ↗ Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed Takeda Phase 3 2005-12-01 The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
NCT00255151 ↗ Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis Completed Takeda Phase 3 2006-01-01 The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
NCT00255164 ↗ Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis Completed Takeda Phase 3 2006-01-01 The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dexlansoprazole

Condition Name

Condition Name for Dexlansoprazole
Intervention Trials
Gastroesophageal Reflux Disease 13
Esophagitis, Reflux 5
Gastroesophageal Reflux 5
Esophagitis, Peptic 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dexlansoprazole
Intervention Trials
Gastroesophageal Reflux 26
Esophagitis, Peptic 17
Esophagitis 12
Heartburn 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dexlansoprazole

Trials by Country

Trials by Country for Dexlansoprazole
Location Trials
United States 461
China 33
Mexico 18
Canada 12
India 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dexlansoprazole
Location Trials
California 19
Arizona 18
Illinois 17
Texas 17
Ohio 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dexlansoprazole

Clinical Trial Phase

Clinical Trial Phase for Dexlansoprazole
Clinical Trial Phase Trials
Phase 4 10
Phase 3 13
Phase 2/Phase 3 1
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dexlansoprazole
Clinical Trial Phase Trials
Completed 34
Unknown status 5
Withdrawn 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dexlansoprazole

Sponsor Name

Sponsor Name for Dexlansoprazole
Sponsor Trials
Takeda 31
Mayo Clinic 2
Takeda Pharmaceuticals North America, Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dexlansoprazole
Sponsor Trials
Industry 35
Other 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
AstraZeneca
Moodys
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.